ABC | Volume 112, Nº5, Maio 2019

Artigo de Revisão Amorim et al Doença renal do diabetes Arq Bras Cardiol. 2019; 112(5):577-587 10. Silva TA, Vasconcelos SML. O controle da glicemia como um fator atenuante do estresse oxidativo da hipertensão arterial. Rev Bras Hipertens. 2011;18(3):113-5. 11. KwonH, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013 Jun 12;4:71. 12. De Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582(1):97-105. 13. Santos JC de F, Valentim IB, de Araújo ORP, Ataide TR, Goulart MOF. Developmentofnonalcoholichepatopathy:Contributionsofoxidativestress and advanced glycation end products. Int J Mol Sci. 2013;14(10):19846-66. 14. Queiroz JC, Alonso-Vale MI, Curi R, Lima FB. Control of adipogenesis by fatty acids. Arq Bras Endocrinol Metabol. 2009;53(5):582-94. 15. Freitas MC, Ceschini FL, Ramallo BT. Insulin resistance associated with obesity: anti-inflammatory effects of physical exercise. R Bras Ci Mov. 2014;22(3):139-47. 16. LagranhaCJ,FiorinoP,CasariniDE,SchaanBD,IrigoyenMC.Molecularbases of diabetic nephropathy. Arq Bras Endocrinol Metabol. 2007;51(6):901-12. 17. Machado UF, Schaan BD, Seraphim PM. Glucose transporters in the metabolic syndrome. Arq Bras Endocrinol Metabol. 2006;50(2):177-89. 18. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1009-22. 19. Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015:2015:948417. 20. Toth-Manikowski S, AttaMG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. 21. Barbosa KBF, Costa NMB, Gonçalves RC, De Paula SO, MinimVPR, Bressan J. Oxidative stress: concept, implications and modulating factors. Rev Nutr. 2010;23(4):629-43. 22. BarreirosALBS,David JM,David JP.Estresseoxidativo:Relaçãoentregeração deespéciesreativasedefesadoorganismo.QuimNova.2006;29(1):113-23. 23. Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol. 2014;171(8):1917-42. 24. Che R, Yuan Y, Huang S, Zhang A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2014;306(4):F367-78. 25. Sharma K. Obesity and diabetic kidney disease: role of oxidant stress and redox balance. Antioxid Redox Signal. 2016;25(4):208-16. 26. Levin A, Djurdjev O. On being better kidney doctors: understanding trajectories, probabilities, predictability, and people. Am J Kidney Dis. 2012;59(4):475-7. 27. Han Q, Zhu H, Chen X, Liu Z. Non-genetic mechanisms of diabetic nephropathy. Front Med. 2017;11(3):319-32. 28. Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017;13(10):629-46. 29. Reis JS, Veloso CA, Mattos RT, Purish S, Nogueira-Machado JA. Oxidative stress:areviewonmetabolicsignaling intype1diabetes.ArqBrasEndocrinol Metab. 2008;52(7):1096-105. 30. Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M, Rafieian- Kopaei M. Role of oxidative stress and inflammatory factors in diabetic kidney disease. Iran J Kidney Dis. 2016;10(6):337-43. 31. Blacker TS, Duchen MR. Investigating mitochondrial redox state using NADH and NADPH autofluorescence. Free Radic Biol Med. 2016 Nov;100:53-65. 32. Geraldes P, King LG. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-31. 33. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007 Aug;(106):S49-53. 34. Kanwar YS, Sun L, Xie P, Liu F, Chen S. A Glimpse of various pathogenic mechanism of diabetic nephropathy. Annu Rev Pathol. 2011;6:395-423. 35. Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: lessons from diabetic eNOS knockout mice. J Diabetes Res. 2014;2014:590541. 36. LimaVL.PapeldaO-glicosilaçãocomN-acetil-glucosamina (O-GlcNAc)nas alterações vasculares associadas a altos níveis de endotelina-1 [dissertação]. Ribeirão Preto: Universidade de São Paulo; 2012. 37. Arsov S, Graaff R, Van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2014;52(1):11-20. 38. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal. 2009;11(12):3071-109. 39. Castro E. The role of advanced glycosylation end products in diabetic nephropathy. Arq Med. 2011;25(1):27-37. 40. Tan ALY, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130-43. 41. Stinghen AE, Massy ZA, Vlassara H, Striker GE, Boullier A. Uremic toxicity of advanced glycation end products in CKD. J Am Soc Nephrol. 2016;27(2)354-70. 42. Matsui T, Higashimoto Y, Nishino Y, Nakamura N, Fukami K, Yamagishi SI. RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy. Diabetes. 2017;66(6):1683-95. 43. Coughlan MT, Sharma K. Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease? Kidney Int. 2016;90(2):272-9. 44. ZhuQ, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14(2):105-20. 45. ChawlaT,SharmaD,SinghA.Roleofthereninangiotensinsystem indiabetic nephropathy. World J Diabetes. 2010;1(5):141-5. 46. Carmines PK. The renal vascular response to diabetes. Curr Opin Nephrol Hypertens. 2010;19(1):85-90. 47. LimAKH. Diabetic nephropathy - complications and tratment. Int J Nephrol Renovasc Dis. 2014 Oct 15;7:361-81. 48. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(5):444-56. 49. VanBurenPN,TotoR.Hypertension indiabeticnephropathy:epidemiology, mechanisms,andmanagement.AdvChronicKidneyDis.2011;18(1):28-41. 50. Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59-74. 51. Márquez E, Riera M, Pascual J, Soler MJ. Renin-angiotensin system within the diabetic podocyte. Am J Physiol Renal Physiol.. 2015;308(1):F1-10. 52. Padda RS, Shi Y, Lo CS., Zhang SL, Chan JS. Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes?. J Diabetes Metab. 2015;6(10). 53. Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal. 2013;19(10):1110-20. 54. Parker MD, Myers EJ, Schelling JR. Na+-H+exchanger-1 (NHE1) regulation in kidney proximal tubule. Cell Mol Life Sci. 2015;72(11):2061-74. 55. Vallés PG, Bocanegra V, Gil LA, Costantino VV.Physiological functions and regulation of the Na + /H + exchanger [NHE1] in renal tubule epithelial cells. Kidney Blood Press Res. 2015;40(5):452-66. 586